Les Laboratoires Servier
http://www.servier.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Les Laboratoires Servier
Servier: Precision Approach To Immunotherapy Will Define New Oncology Era
Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.
Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops
Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.
Allogene Frustrated By FDA’s Delayed CAR-T Trial Review
Allogene hopes its off-the-shelf CAR-T can begin a potentially pivotal Phase II study by the end of this year but is frustrated by an “under-resourced and overworked FDA.”
Deal Watch: GSK Gets Rights To Spero’s Phase III Antibiotic
GSK takes equity stake in Spero, and global rights to tebipenem except for certain Asian markets. Merck KGaA gets rights to Nerviano’s next-generation PARP inhibitor for cancer.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Biogaran SAS
- Egis Pharmaceuticals plc
- WeHealth
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.